1. Polyclonal PAX8 expression in carcinomas of the biliary tract - Frequent non-specific staining represents a potential diagnostic pitfall.
- Author
-
Zong Y, Xiong Y, Dresser K, Yang M, and Bledsoe JR
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma metabolism, Cholangiocarcinoma metabolism, Cholangiocarcinoma secondary, Diagnosis, Differential, Diagnostic Errors prevention & control, Female, Humans, Immunohistochemistry methods, Male, Middle Aged, Neoplasm Metastasis genetics, Neoplasm Metastasis pathology, Neoplasm Staging methods, Pathologists education, Pelvic Neoplasms secondary, Retrospective Studies, Staining and Labeling methods, Biliary Tract pathology, Biomarkers, Tumor metabolism, Carcinoma diagnosis, PAX8 Transcription Factor metabolism, Staining and Labeling statistics & numerical data
- Abstract
Paired box protein 8 (PAX8) is a transcription factor that is considered a relatively specific marker of carcinomas of the thyroid, kidney, and Müllerian/Wolffian duct derivatives. Unexpected PAX8 immunoreactivity has occasionally been reported in other tumors. The frequency of PAX8 expression in carcinomas of the biliary tract is not well studied. We evaluated the immunohistochemical expression of PAX8 in 73 cases of biliary tract carcinoma. We found that 28 of 73 (38%) biliary tract carcinomas had variable immunoreactivity for PAX8, assessed by a widely used polyclonal antibody (ProteinTech Group, Chicago, IL). This included 3 (4%) of cases with strong diffuse, and 14 (19%) of cases with strong focal staining. Strong PAX8 expression was more frequent in distal bile duct carcinomas than other biliary sites (p = 0.015), and showed a weak association with advanced T stage (T3-T4 versus T1-T2; p = 0.09). No correlation was observed between PAX8 positivity and age at diagnosis, gender, or lymph node metastasis. The 28 polyclonal PAX8-positive cases were largely negative for monoclonal PAX8 and PAX6 immunostains, with only rare tumor cells with weak immunoreactivity being present in a subset of cases. We show that a substantial fraction of biliary tract carcinomas exhibit immunoreactivity with a widely used polyclonal PAX8 antibody. Pathologists should be aware of this potential pitfall during the diagnostic workup of hepatobiliary lesions to avoid misdiagnosis as a metastasis from a PAX8-positive tumor., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF